Delving into the Latest Updates on Geom Therapeutics, Inc. with Synapse

概览

关联

1

项与 Geom Therapeutics, Inc. 相关的药物

LCB10-0200

靶点

PBPs

作用机制

PBPs抑制剂

在研机构

LigaChem Biosciences, Inc.

原研机构

LigaChem Biosciences, Inc.

在研适应症

革兰氏阴性菌感染

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

1

项与 Geom Therapeutics, Inc. 相关的临床试验

ACTRN12618001980224 / Suspended临床1期

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT-1 in Healthy Adult Subjects.

开始日期2019-03-14

申办/合作机构

Clinical Network Services Pty Ltd.

[+1]

100 项与 Geom Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Geom Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Geom Therapeutics, Inc. 相关的文献（医药）

2021-12-01·The Journal of Antibiotics4区 · 医学

In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens

4区 · 医学

Article

作者: Zumbrun, Steven D ; Hannah, Brendan ; Lemmon, Margaret M ; Pysz, Lisa M ; Halasohoris, Stephanie A ; Panchal, Rekha G ; Scarff, Jennifer M ; Biek, Donald ; Lembirik, Sanae

AbstractAntimicrobial-resistance (AMR) has become an increasingly difficult issue to overcome for bacteria associated with both community- and hospital-acquired infections as well as potential biodefense threats. The need to identify new therapeutics of novel classes and/or with unique mechanisms is critical to combatting AMR in the coming years. GT-1 (LCB10-0200), a siderophore-linked cephalosporin, is one such novel option and is formulated to be used either alone or in combination with a novel broad-spectrum β-lactamase inhibitor, GT-055 (LCB18-055). This study assessed the in vitro and in vivo efficacy of GT-1 and GT-055 against a broad array of multi-drug resistant and biothreat pathogens. Here, we demonstrated sub-4 µg ml−1 efficacy against a number of pathogens in vitro. We further determined that in mice infected via aerosol route with Yersinia pestis, efficacy of GT-1/GT-055 treatment is at least equivalent to the comparator antibiotic, ciprofloxacin.

100 项与 Geom Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Geom Therapeutics, Inc. 相关的转化医学

登录后查看更多信息